We are resuming coverage of Trovagene after reassigning research coverage to a different analyst. The company yesterday released interim results from a Phase II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (CRC) patients carrying KRAS mutations. Onvansertib is an inhibitor of PLK1. In experimental models, the drug kills cancer cells harboring KRAS mutations. Results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held in San Francisco on January 25, 2020. Read More >>